Close Menu
Home » Asuragen, Wave Life Sciences to Develop Companion Diagnostics for Huntington's Disease Therapies

Asuragen, Wave Life Sciences to Develop Companion Diagnostics for Huntington's Disease Therapies

Nov 25, 2019
|
staff reporter

NEW YORK – Molecular diagnostics company Asuragen announced on Monday that it is collaborating with genetic medicines developer Wave Life Sciences to develop and commercialize companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Ah, That's What It Is

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

Billions Requested

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

What to Do

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

PNAS Papers on Heart Transplant Rejection, CAR-T Profiling, Thiopurine Toxicity Variants

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

What's Popular?

In Business News

  1. Guardant Health Q4 Revenues Up 91 Percent

  2. Karius Raises $165M in Series B Financing Round

  3. Twist Bioscience Adds Sample Prep Tech to Miroculus Automation Platform

  4. Capsulomics, Johns Hopkins Partner on Esophageal Cancer, Barrett's Esophagus Research

  5. Exact Sciences Offering $1B of Convertible Senior Notes

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.